Abbott/SangStat May Launch Oral Solution Gengraf To Replace SangCya
Executive Summary
SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.
You may also be interested in...
Bioequivalence Studies Reporting Rule Will Boost Submissions By 10% – FDA
A proposed rule to require ANDA sponsors to submit all bioequivalence studies they complete would increase annual BE study reports by 10%, FDA estimates
Bioequivalence Studies Reporting Rule Will Boost Submissions By 10% – FDA
A proposed rule to require ANDA sponsors to submit all bioequivalence studies they complete would increase annual BE study reports by 10%, FDA estimates
Novartis Offers Gengraf Patients Transition Monitoring If Generic Is Pulled
Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted